Enterprise Value
129.2M
Cash
54.08M
Avg Qtr Burn
-18.78M
Short % of Float
6.79%
Insider Ownership
20.74%
Institutional Own.
30.76%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Omidubicel (NiCord) Details Hematologic malignancies | Approved Quarterly sales | |
GDA-201 Details Non-Hodgkin lymphoma, Multiple myeloma | Phase 1 Data readout |